Hopital Prive du Confluent

Nantes BP 20215 44202 Cedex 2

0 studies enrolling now · 2 studies all time

What they study most

BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Neoplasms

Studies at this site

• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed
• A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) — Stopped early